NEPC tumors for recurrent molecular alterations and determine their functional and clinical impact. She will identify a genomic profile that distinguishes NEPC from the more common type of prostate cancer, prostate adenocarcinoma, and evaluate the impact of NEPC-associated alterations on patient outcomes and their ability to predict patient response to available therapies. Her goal is to improve our understanding of molecular events associated with disease progression and help develop strategies toward preventing NEPC. Distinguishing NEPC will help identify prostate cancer patients unlikely to benefit from additional AR-targeted strategies and select patients for novel targeted treatment approaches for NEPC.
Dr. Beltran works under the mentorship of Mark A. Rubin, MD, at Weill Medical College of Cornell University, New York, New York.
Christine M. Lovly, MD, PhD
Lung cancer is responsible for more cancer-related deaths in the U.S. and worldwide each year than any other cancer. Historically, patients with advanced metastatic disease have been treated with conventional chemotherapy. Recently, however, subsets of lung cancer patients have been identified with specific molecular alterations that allow for treatment with rationally chosen targeted therapies. One molecular subset of lung cancer is characterized by the presence of alterations in a protein called ALK tyrosine kinase. Patients with lung cancers that harbor ALK fusions derive significant clinical benefit from a newly approved drug that blocks the action of the mutant ALK. Unfortunately, the degree and duration of tumor response to ALK inhibitor drugs varies, and patients inevitably develop progressive disease, or "acquired resistance." Additional strategies are needed to improve the treatment of these lung cancer patients.
Dr. Lovly's goal is to develop novel treatment strategies for ALK positive lung cancer.
She plans to improve our understanding of how ALK fusionsPage: 1 2 3 4 5 6 7 Related biology news :1
. Damon Runyon Cancer Research Foundation grants prestigious awards to 17 young scientists2
. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research3
. ACRG and BGI report new evidence for the genetic bases of liver cancer4
. Cancer is a result of a default cellular safe mode, physicist proposes5
. Continued research needed on treatment for women with lung cancer who are never smokers6
. TGen and Ventana Medical Systems Inc. join forces to fight cancer7
. National Institutes of Health to fund research probing proteins linked to cancer, diabetes8
. Herding cancer cells to their death9
. No danger of cancer through gene therapy virus10
. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer11
. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors